Transparency and access to full information for the fatal or serious toxicity risks, low efficacy and high price of deferasirox, could increase the prospect of improved iron chelation therapy worldwide.
Kontoghiorghes
George J
GJ
D058186:Acute Kidney Injury / Q000139:chemically induced; D001565:Benzoates / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D015913:Chelation Therapy; D003362:Cost-Benefit Analysis; D000077588:Deferasirox; D000077543:Deferiprone; D003676:Deferoxamine / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D004345:Drug Industry; D006801:Humans; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D019190:Iron Overload / Q000209:etiology / Q000628:therapy; D011728:Pyridones / Q000191:economics / Q000627:therapeutic use; D065227:Transfusion Reaction; D014230:Triazoles / Q000009:adverse effects* / Q000191:economics / Q000627:therapeutic use; D014342:Truth Disclosure
D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D003676:Deferoxamine; D000077588:Deferasirox